Trasylol News

 

Is this the end of the Trasylol story?

-FiercePharma

05/15/2008 - A new study could be the last nail in Trasylol's coffin. In a head-to-head comparison of Trasylol (aprotinin) and two other anti-bleeding meds, patients getting Trasylol during heart surgery were much more likely to die than patients on the other meds. "In all likelihood, this is the end of the aprotinin story," two researchers wrote in a New England Journal of Medicine editorial accompanying the study's publication.

Bayer, you'll recall, temporarily suspended Trasylol sales last fall when this government-funded Canadian study was stopped early because of the death rates among patients using that drug. An analysis of the data showed Trasylol boosted the chance of death by 54 percent, with 6 percent of patients using that drug dying within 30 days of surgery, compared with 4 percent on the other two drugs.

Bayer faces some 80 lawsuits over the drug, claiming that Trasylol caused unnecessary deaths and that the company hid evidence of its potential risks. Responding to the NEJM article, the company said it is still deciding what to do about the med.

 

Ennis & Ennis, P.A. is representing individuals that have been harmed as a result of Trasylol side effects. If you or a loved one have suffered as a result of Trasylol side effects such as kidney failure, heart attack, or stroke you may be entitled to compensation. For more information about a Trasylol lawsuit, a possible Trasylol recall, or for questions regarding Trasylol class action lawsuits fill out our free Trasylol case evaluation . Our on-staff nurse and attorneys are standing by to answer any questions you may have regarding Trasylol side effects, a possible Trasylol class action lawsuit, or any other type of Trasylol litigation.